-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Molecular Partners Highlights Clinical Development Progress And 2026 Milestones, Including MP0712 Phase 1/2a Initiation With First Dosing Expected Q1 2026 And Multiple Oncology Programs Advancing

Benzinga·01/12/2026 07:36:10
Listen to the news

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026

Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026

Phase 2 investigator-initiated trial of MP0317 now open with patient dosing ongoing, exploring MP0317 in combination with standard-of-care for patients with cholangiocarcinoma

Phase 1/2a trial of multi-specific T cell engager MP0533 ongoing, update on clinical development path planned for H1 2026